Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eylea, Avastin Both Get A Boost From NIH Comparative Study In DME

This article was originally published in The Pink Sheet Daily

Executive Summary

The first head-to-head comparison of Eylea, Avastin and Lucentis in diabetic macular edema shows a superior benefit for Eylea in patients with more advanced vision loss and that Avastin is as effective as the other two drugs in other patients.

You may also be interested in...



Roche: Slow And Steady Wins The Race

The firm got off to a solid start in 2016, which should see its biggest launches in years, but its core strength remains executing long-term management of its key franchises.

Deal Watch: Bristol Places Early Wager On Padlock's Autoimmune Potential

Regeneron and Bayer look to build on their past success collaborating in ophthalmology by partnering to develop an Eylea successor. Sun Pharma builds its portfolio with 13 products from Novartis.

Regeneron/Bayer Partnership Seeks To Build Upon Eylea's Success

Latest ophthalmologic collaboration between the partners seeks to create an Eylea successor by combining aflibercept with an Ang2 antibody.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS078175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel